MLKL is also downregulated in pancreatic cancer and cervical squamous cell carcinoma, where low levels of MLKL in plasma predict poor prognosis in pancreatic and ovarian cancer (Ruan et al., 2015; Seldon et al., 2016). Here, MLKL is linked to ovarian cancer.